Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations w...

詳細記述

書誌詳細

出版年:	ESC Heart Failure
主要な著者:	Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2025-04-01
主題:	vericiguat soluble guanylate cyclase stimulators heart failure clinical trial
オンライン･アクセス:	https://doi.org/10.1002/ehf2.15134